Huestis Marilyn A, Gustafson Richard A, Moolchan Eric T, Barnes Allan, Bourland James A, Sweeney Stacy A, Hayes Eugene F, Carpenter Patrick M, Smith Michael L
Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, United States.
Forensic Sci Int. 2007 Jul 4;169(2-3):129-36. doi: 10.1016/j.forsciint.2006.08.005. Epub 2006 Sep 11.
Fifty-three head hair specimens were collected from 38 males with a history of cannabis use documented by questionnaire, urinalysis and controlled, double blind administration of delta9-tetrahydrocannabinol (THC) in an institutional review board approved protocol. The subjects completed a questionnaire indicating daily cannabis use (N=18) or non-daily use, i.e. one to five cannabis cigarettes per week (N=20). Drug use was also documented by a positive cannabinoid urinalysis, a hair specimen was collected from each subject and they were admitted to a closed research unit. Additional hair specimens were collected following smoking of two 2.7% THC cigarettes (N=13) or multiple oral doses totaling 116 mg THC (N=2). Cannabinoid concentrations in all hair specimens were determined by ELISA and GCMSMS. Pre- and post-dose detection rates did not differ statistically, therefore, all 53 specimens were considered as one group for further comparisons. Nineteen specimens (36%) had no detectable THC or 11-nor-9-carboxy-THC (THCCOOH) at the GCMSMS limits of quantification (LOQ) of 1.0 and 0.1 pg/mg hair, respectively. Two specimens (3.8%) had measurable THC only, 14 (26%) THCCOOH only, and 18 (34%) both cannabinoids. Detection rates were significantly different (p<0.05, Fishers' exact test) between daily cannabis users (85%) and non-daily users (52%). There was no difference in detection rates between African-American and Caucasian subjects (p>0.3, Fisher's exact test). For specimens with detectable cannabinoids, concentrations ranged from 3.4 to >100 pg THC/mg and 0.10 to 7.3 pg THCCOOH/mg hair. THC and THCCOOH concentrations were positively correlated (r=0.38, p<0.01, Pearson's product moment correlation). Using an immunoassay cutoff concentration of 5 pg THC equiv./mg hair, 83% of specimens that screened positive were confirmed by GCMSMS at a cutoff concentration of 0.1 pg THCCOOH/mg hair.
通过问卷调查、尿液分析以及在机构审查委员会批准的方案中对delta9-四氢大麻酚(THC)进行对照双盲给药,从38名有大麻使用史的男性中收集了53份头部毛发样本。受试者完成了一份问卷,表明每日使用大麻(N = 18)或非每日使用,即每周吸食一至五支大麻香烟(N = 20)。药物使用情况也通过大麻素尿液分析呈阳性记录,从每个受试者身上采集一份毛发样本,他们被收治到一个封闭的研究单元。在吸食两支含2.7% THC的香烟后(N = 13)或口服多剂总计116 mg THC后(N = 2),又采集了额外的毛发样本。所有毛发样本中的大麻素浓度通过酶联免疫吸附测定(ELISA)和气相色谱-串联质谱(GCMSMS)测定。给药前和给药后的检测率在统计学上没有差异,因此,将所有53个样本视为一组进行进一步比较。在GCMSMS分别为1.0和0.1 pg/mg毛发的定量限(LOQ)下,19个样本(36%)未检测到THC或11-去甲-9-羧基-THC(THCCOOH)。两个样本(3.8%)仅检测到可测量的THC,14个(26%)仅检测到THCCOOH,18个(34%)两种大麻素都检测到。每日大麻使用者(85%)和非每日使用者(52%)之间的检测率有显著差异(p<0.05,Fisher精确检验)。非裔美国人和白种人受试者之间的检测率没有差异(p>0.3,Fisher精确检验)。对于检测到大麻素的样本,浓度范围为3.4至>100 pg THC/mg毛发和0.10至7.3 pg THCCOOH/mg毛发。THC和THCCOOH浓度呈正相关(r = 0.38,p<0.01,Pearson积矩相关)。使用5 pg THC当量/mg毛发的免疫测定临界浓度,83%筛查呈阳性的样本在0.1 pg THCCOOH/mg毛发的临界浓度下通过GCMSMS得到确认。